Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692627 | 0.91 | CREBBP (0.49) | CREBBPMAOAMAOBBRD4ALDH1A1 | |
| SCHEMBL2014698 | 0.90 | CREBBP (0.52) | CREBBPMAOAMAOBBRD4 | |
| SCHEMBL2017862 | 0.90 | CREBBP (0.43) | CREBBPMAOAMAOBBRD4HTR1A | |
| SCHEMBL693335 | 0.89 | MAOB (0.46) | CREBBPMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL693785 | 0.86 | HTR1A (0.43) | CREBBPMAOBHTR1ASLC6A2SLC6A4 | |
| SCHEMBL691343 | 0.85 | HTR2C (0.47) | — | |
| SCHEMBL2015193 | 0.85 | HTR2C (0.47) | — | |
| SCHEMBL2017687 | 0.84 | CREBBP (0.40) | CREBBPBRD4 | |
| SCHEMBL692525 | 0.84 | CREBBP (0.40) | CREBBPBRD4 | |
| SCHEMBL2016837 | 0.84 | CREBBP (0.40) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | claimed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2421870-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-03-09 | — | — | EP | claimed |
| EP-2522671-B1 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC (US) | 2016-01-20 | — | — | EP | claimed |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | claimed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | claimed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | claimed |
| EP-2560973-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | claimed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | claimed |
| WO-2011133182-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | claimed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | claimed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | claimed |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9701679-B2 | Modulators of 5-HT receptors and methods of use thereof | Abb Vie Deutschland GmbH & Co. KG (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011133182-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CREBBP 2160/4885MAOA 283/4885MAOB 194/4885 |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CREBBP 2160/4885MAOA 283/4885MAOB 194/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CREBBP 2160/4885MAOA 283/4885MAOB 194/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CREBBP 2160/4885MAOA 283/4885MAOB 194/4885 |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CREBBP 2160/4885MAOA 283/4885MAOB 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.